Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157638 | 0.86 | HSD11B1 (0.58) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL6503057 | 0.82 | HSD11B1 (0.52) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL6504698 | 0.81 | HSD11B1 (0.62) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL5160276 | 0.81 | HSD11B1 (0.62) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL6502476 | 0.80 | HSD11B1 (0.57) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL5177177 | 0.79 | HSD11B1 (0.56) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL5157056 | 0.79 | HSD11B1 (0.53) | HSD11B1L3MBTL1HSD17B10EPHX2 | |
| SCHEMBL5157962 | 0.78 | EPHX2 (0.46) | HSD11B1EPHX2EPHX1KMT2A | |
| SCHEMBL6510781 | 0.77 | HSD11B1 (0.56) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL12640444 | 0.75 | HSD11B1 (0.70) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD11B1 2/4885L3MBTL1 4160/4885HSD17B10 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.